Cargando…
Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts.
The clinical use of anti-oestrogens in breast cancer therapy has traditionally been restricted to tumours that contain measurable oestrogen receptor protein. However, it is now widely recognised that the clinical response to adjuvant anti-oestrogen therapy appears to be independent of the oestrogen...
Autores principales: | Colletta, A. A., Wakefield, L. M., Howell, F. V., van Roozendaal, K. E., Danielpour, D., Ebbs, S. R., Sporn, M. B., Baum, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971440/ https://www.ncbi.nlm.nih.gov/pubmed/1698443 |
Ejemplares similares
-
Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen.
por: Benson, J. R., et al.
Publicado: (1996) -
Differences in oestrogen receptors in malignant and normal breast tissue as identified by the binding of a new synthetic progestogen.
por: Iqbal, M. J., et al.
Publicado: (1986) -
Induction of transforming growth factor beta in hormonally treated human prostate cancer.
por: Muir, G. H., et al.
Publicado: (1994) -
Progress towards unlocking the secrets of oestrogen receptor beta in breast cancer
por: Speirs, V, et al.
Publicado: (2006) -
Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)